Self-reported use of novel psychoactive substances in a US nationally representative survey: Prevalence, correlates, and a call for new survey methods to prevent underreporting

Drug and Alcohol Dependence

Volumn 156, Issue , 2015, Pages 112-119

  Palamar, Joseph J ^a,b,c   Martins, Silvia S ^d   Su, Mark K ^e   Ompad, Danielle C ^b,c,d  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b NEW YORK UNIVERSITY   (United States)

^c NEW YORK UNIVERSITY   (United States)

^d Department of Medicine   (United States)

^e NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Novel psychoactive drugs; Novel psychoactive substances; Phenethylamines; Synthetic cannabinoids; Synthetic cathinones; Tryptamines

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; CANNABINOID; COCAINE; ILLICIT DRUG; LYSERGIDE; PHENETHYLAMINE DERIVATIVE; PSYCHOTROPIC AGENT; TRYPTAMINE DERIVATIVE; ALKALOID; CATHINONE; MIDOMAFETAMINE; N,N DIMETHYLTRYPTAMINE; PSYCHEDELIC AGENT; STREET DRUG;

ADOLESCENT; ADULT; ARTICLE; CAUCASIAN; CHILD; CORRELATIONAL STUDY; DRUG USE; FEMALE; HEALTH SURVEY; HUMAN; LOWEST INCOME GROUP; MALE; PREVALENCE; PRIORITY JOURNAL; SELF REPORT; SEX DIFFERENCE; SUBSTANCE USE; UNITED STATES; URBAN AREA; QUESTIONNAIRE; STATISTICAL MODEL; SUBSTANCE-RELATED DISORDERS; YOUNG ADULT;

ADOLESCENT; ADULT; ALKALOIDS; CANNABINOIDS; COCAINE; FEMALE; HALLUCINOGENS; HUMANS; LOGISTIC MODELS; MALE; N,N-DIMETHYLTRYPTAMINE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; PHENETHYLAMINES; PREVALENCE; PSYCHOTROPIC DRUGS; SELF REPORT; STREET DRUGS; SUBSTANCE-RELATED DISORDERS; SURVEYS AND QUESTIONNAIRES; TRYPTAMINES; YOUNG ADULT;

EID: 84946489216     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2015.08.028     Document Type: Article

References (51)

1. American Civil Liberties Union The War on Marijuana in Black and White: Billions of Dollars Wasted on Racially Biased Arrests 2013, ACLU Foundation, New York, https://www.aclu.org/sites/default/files/assets/1114413-mj-report-rfs-rel1.pdf (accessed 2.05.15).
2. Barratt M.J., Ferris J.A., Winstock A.R. Use of Silk Road, the online drug marketplace, in the United Kingdom, Australia and the United States. Addiction 2014, 109:774-783.
3. Butler J.S., Coffey L.E., Griffin A.B., Hunter D.C., Johnson I., Liu S., Livengood M., Martin P.C., McKamey A.C., Morton K.B., Myers S.K., Parsons S., Pratt J., Riggsbee B.H., Zelko H. Data Collection Final Report: Prepared for the 2011 Methodological Resource Book 2012, RTI International, Research Triangle Park, NC, http://archive.samhsa.gov/data/2k12/NSDUH2011MRB/NSDUHmrbDCFR2011.pdf (accessed 13.07.15).
4. Carhart-Harris R.L., King L.A., Nutt D.J. A web-based survey on mephedrone. Drug Alcohol Depend. 2011, 118:19-22.
5. Cohen J.A. The highs of tomorrow: why new laws and policies are needed to meet the unique challenges of synthetic drugs. J. Law Health 2014, 27:164-185.
6. Community Epidemiology Work Group Epidemiologic Trends in Drug Abuse: Proceedings of the Community Epidemiology Work Group 2014, National Institute on Drug Abuse, Bethesda, MD, http://www.drugabuse.gov/sites/default/files/cewgjune2014.pdf (accessed 2.05.15).
7. Dart R.C., Bronstein A.C., Spyker D.A., Cantilena L.R., Seifert S.A., Heard S.E., Krenzelok E.P. Poisoning in the United States: 2012 emergency medicine report of the national poison data system. Ann. Emerg. Med. 2015, 65:416-422.
8. Elliott S., Evans J. A 3-year review of new psychoactive substances in casework. Forensic Sci. Int. 2014, 243:55-60.
9. European Monitoring Centre for Drugs and Drug Addiction New Drugs in Europe, 2012 2012, http://www.emcdda.europa.eu/attachements.cfm/att_212366_EN_EMCDDA-Europol%202012%20Annual%20Report_final.pdf (accessed 28.10.14).
10. European Monitoring Centre for Drugs and Drug Addiction New Psychoactive Substances in Europe. An update from the EU Early Warning System (March 2015) 2015, Publications Office of the European Union, Luxembourg, http://www.emcdda.europa.eu/attachements.cfm/att_235958_EN_TD0415135ENN.pdf (accessed 1.05.15).
11. Federal Register Project: 2015 National Survey on Drug Use and Health (OMB No. 0930-0110)-Revision. Fed. Regis. 2014, 79(121):35760.
12. Forrester M.B. 2C series phenethylamine derivative exposures in Texas. Subst. Abuse 2013, 34:81-82.
13. Forrester M.B. NBOMe designer drug exposures reported to Texas poison centers. J. Addict. Dis. 2014, 33:196-201.
14. Golub A., Johnson B.D., Dunlap E. The race/ethnicity disparity in misdemeanor marijuana arrests in New York City. Criminol. Public Policy 2007, 6:131-164.
15. Halkitis P.N., Palamar J.J., Mukherjee P.P. Poly-club-drug use among gay and bisexual men: a longitudinal analysis. Drug Alcohol Depend. 2007, 89:153-160.
16. Heeringa S., West B.T., Berglund P.A. Applied Survey Data Analysis 2010, Chapman & Hall/CRC, Boca Raton, FL.
17. Helander A., Beck O., Hagerkvist R., Hulten P. Identification of novel psychoactive drug use in Sweden based on laboratory analysis-initial experiences from the STRIDA project. Scand. J. Clin. Lab. Investig. 2013, 73:400-406.
18. Hill S.L., Harbon S.C., Coulson J., Cooper G.A., Jackson G., Lupton D.J., Vale J.A., Thomas S.H. Methoxetamine toxicity reported to the National Poisons Information Service: clinical characteristics and patterns of enquiries (including the period of the introduction of the UK's first Temporary Class Drug Order). Emerg. Med. J. 2014, 31:45-47.
19. Hill S.L., Thomas S.H. Clinical toxicology of newer recreational drugs. Clin Toxicol. 2011, 49:705-719.
20. Johnson B.D., Golub A., Dunlap E., Sifaneck S.J. An analysis of alternatives to New York City's current marijuana arrest and detention policy. Policing 2008, 31:226-250.
21. Johnson P.S., Johnson M.W. Investigation of "bath salts" use patterns within an online sample of users in the United States. J. Psychoact. Drugs 2014, 46:369-378.
22. Kelly B.C., Wells B.E., Pawson M., Leclair A., Parsons J.T., Golub S.A. Novel psychoactive drug use among younger adults involved in US nightlife scenes. Drug Alcohol Rev. 2013, 32:588-593.
23. Khazan M. Synthetic Drugs Are Multiplying Too Fast for Regulators to Outlaw Them 2013, The Atlantic.
24. King L.A., Nutt D.J., Independent Scientific Committee on Drugs Deaths from "legal highs": a problem of definitions. Lancet 2014, 383:952.
25. Law R., Schier J., Martin C., Chang A., Wolkin A. Notes from the field: increase in reported adverse health effects related to synthetic cannabinoid use-United States, January-May 2015. Morb. Mortal. Wkly. Rep. 2015, 64:618-619.
26. LeBaron P., Dean E. 2011 National Survey on Drug Use and Health: CAI Specifications for Programming, English Version 2010, Research Triangle Institute, Research Triangle Park, NC, http://archive.samhsa.gov/data/2k12/NSDUH2011MRB/2k11Q.pdf (accessed 13.07.15).
27. Miech R.A., Johnston L.D., O'Malley P.M., Bachman J.G., Schulenberg J.E. Monitoring the Future National Survey Results on Drug Use, 1975-2014. Secondary School Students 2015, vol. I. Institute for Social Research, The University of Michigan, Ann Arbor, http://www.monitoringthefuture.org/pubs/monographs/mtf-vol1_2014.pdf (accessed 25.08.15).
28. Mohr A.L.A., Yeakel J.K., Friscia M., Logan B.K. Recreational drug use trends and emerging analytes identified in blood, urine, and/or oral fluid from attendees at an electronic dance music festival 2015, Center for Forensic Science Research & Education. Presentation at Toxicology Section-2015, http://www.aafs.org/sites/default/files/2015/abstracts/K9.pdf (accessed 25.08.15).
29. Morley K.I., Lynskey M.T., Moran P., Borschmann R., Winstock A.R. Polysubstance use, mental health and high-risk behaviours: results from the 2012 Global Drug Survey. Drug Alcohol Rev. 2015, 34:427-437.
30. Murphy C.M., Dulaney A.R., Beuhler M.C., Kacinko S. "Bath salts" and "plant food" products: the experience of one regional US poison center. J. Med. Toxicol. 2013, 9:42-48.
31. National Institute on Drug Abuse Assessing Drug Abuse Within and Across Communities: Community Epidemiology Surveillance Networks on Drug Abuse 2006, National Institutes of Health, Bethesda, MD, http://www.drugabuse.gov/sites/default/files/assessingdrugabuse.pdf (accessed 3.05.15).
32. Palamar J.J. An examination of opinions toward marijuana policies among high school seniors in the United States. J. Psychoact. Drugs 2014, 46:351-361.
33. Palamar J.J. "Bath salt" use among a nationally representative sample of high school seniors in the United States. Am. J. Addict. 2015, 24:488-491.
34. Palamar J.J., Acosta P. Synthetic cannabinoid use in a nationally representative sample of US high school seniors. Drug Alcohol Depend. 2015, 149:194-202.
35. Palamar J.J., Ompad D.C., Petkova E. Correlates of intentions to use cannabis among US high school seniors in the case of cannabis legalization. Int. J. Drug Policy 2014, 25:424-435.
36. Senate Caucus on International Narcotics Control Dangerous Synthetic Drugs (statement of Joseph T. Rannazzisi, Deputy Assistant Administrator, Drug Enforcement Administration, U.S. Department of Justice) 2013.
37. Substance Abuse and Mental Health Services Administration National Survey on Drug Use and Health, 2005. ICPSR 04596-v4. Inter-university Consortium for Political and Social Research, 2013-06-24 2013, http://www.icpsr.umich.edu/icpsrweb/ICPSR/studies/4596 (accessed 25.08.15).
38. Substance Abuse and Mental Health Services Administration National Survey on Drug Use and Health, 2006. ICPSR 21240-v6. Inter-university Consortium for Political and Social Research, 2013-06-21 2013, http://www.icpsr.umich.edu/icpsrweb/ICPSR/studies/21240 (accessed 25.08.15).
39. Substance Abuse and Mental Health Services Administration Results from the 2013 National Survey on Drug Use and Health: Summary of National Findings 2014, http://www.samhsa.gov/data/sites/default/files/NSDUHresultsPDFWHTML2013/Web/NSDUHresults2013.pdf (accessed 25.08.15).
40. U.S.Drug Enforcement Administration, Office of Diversion Control National Forensic Laboratory Information System Special Report: Emerging 2C-Phenethylamines, Piperazines, and Tryptamines in NFLIS, 2006-2011 2012, U.S. Drug Enforcement Administration, Springfield, VA, https://www.nflis.deadiversion.usdoj.gov/DesktopModules/ReportDownloads/Reports/NFLIS_SR_Emerging_II.pdf (accessed 3.05.15).
41. U.S.Drug Enforcement Administration, Office of Diversion Control National Forensic Laboratory Information System Special Report: Synthetic Cannabinoids and Synthetic Cathinones Reported in NFLIS, 2010-2013 2014, U.S. Drug Enforcement Administration, Springfield, VA, https://www.nflis.deadiversion.usdoj.gov/DesktopModules/ReportDownloads/Reports/NFLIS_SR_CathCan_508.pdf (accessed 26.04.15).
42. U.S.Drug Enforcement Administration, Office of Diversion Control National Forensic Laboratory Information System: Midyear Report 2014 2015, U.S. Drug Enforcement Administration, Springfield, VA, https://www.nflis.deadiversion.usdoj.gov/DesktopModules/ReportDownloads/Reports/NFLIS2014MY.pdf (accessed 3.05.15).
43. United Kingdom Focal Point on Drugs United Kingdom Drug Situation: Annual Report to the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) 2014, United Kingdom Focal Point at Public Health England, London, http://www.nta.nhs.uk/uploads/uk-focal-point-report-2014.pdf (accessed 26.04.15).
44. United Nations Office on Drugs and Crime World Drug Report 2014 2014, https://www.unodc.org/documents/wdr2014/World_Drug_Report_2014_web.pdf (accessed 26.04.15).
45. Uosukainen H., Tacke U., Winstock A.R. Self-reported prevalence of dependence of MDMA compared to cocaine, mephedrone and ketamine among a sample of recreational poly-drug users. Int. J. Drug Policy 2015, 26:78-83.
46. Van Hout M.C., Brennan R. 'Heads held high': an exploratory study of legal highs in pre-legislation Ireland. J. Ethn. Subst. Abuse 2011, 10:256-272.
47. Vazirian M., Jerry J.M., James J., Dale R.M. Bath salts in the emergency department: a survey of emergency clinicians' experience with bath salts-intoxicated patients. J. Addict. Med. 2015, 9:94-98.
48. Winstock A., Lynskey M., Borschmann R., Waldron J. Risk of emergency medical treatment following consumption of cannabis or synthetic cannabinoids in a large global sample. J. Psychopharmacol. 2015, 29:698-703.
49. Winstock A.R., Barratt M.J. Synthetic cannabis: a comparison of patterns of use and effect profile with natural cannabis in a large global sample. Drug Alcohol Depend. 2013, 131:106-111.
50. Winstock A.R., Kaar S., Borschmann R. Dimethyltryptamine (DMT): prevalence, user characteristics and abuse liability in a large global sample. J. Psychopharmacol. 2014, 28:49-54.
51. Wood K.E. Exposure to bath salts and synthetic tetrahydrocannabinol from 2009 to 2012 in the United States. J. Pediatr. 2013, 163:213-216.